Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: the PanACEA approach

Anna-Maria Mekota*, Stephen H. Gillespie, Michael Hoelscher, Andreas H. Diacon, Rodney Dawson, Gavin Churchyard, Ian Sanne, Lilian Minja, Gibson Kibiki, Leonard Maboko, Shabir Lakhi, Moses Joloba, Abraham Alabi, Bruce Kirenga, Timothy D. McHugh, Martin P. Grobusch, Martin J. Boeree

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Introduction The Pan-African Consortium for the Evaluation of Anti-Tuberculosis Antibiotics (PanACEA) was designed to build tuberculosis (TB) trial capacity whilst conducting clinical trials on novel and existing agents to shorten and simplify TB treatment. PanACEA has now established a dynamic network of 11 sub-Saharan clinical trial sites and four European research institutions.

Objectives In 2011, a capacity development program, funded by the European & Developing Countries Clinical Trials Partnership (EDCTP), was launched with four objectives, aiming at strengthening collaborating TB research sites to reach the ultimate goal of becoming self-sustainable institutions: networking; training; conducting clinical trials; and infrastructure scaling-up of sites. 

Methods Assessment in six sub-Saharan TB-endemic countries (Gabon, Kenya, South Africa, Tanzania, Uganda and Zambia) were performed through a structured questionnaire, site visits, discussion with the PanACEA consortium, setting of milestones and identification of priorities and followed-up with evaluations of each site. The results of this needs-based assessment was then translated into capacity development measures. 

Results In the initial phase, over a 4-year period (March 2011 – June 2014), the programme scaled-up six sites; conducted a monitoring training program for 11 participants; funded five MSc and four PhD students, fostering gender balance; conducted four epidemiological studies; supported sites to conduct five Phase II studies and formed a sustainable platform for TB research (panacea-tb.net). 

Conclusion Our experience of conducting TB clinical trials within the PanACEA programme environment of mentoring, networking and training has provided a sound platform for establishing future sustainable research centres. Our goal of facilitating emergent clinical TB trial sites to better initiate and lead research activities has been mostly successful.
Original languageEnglish
Article number106776
Number of pages18
JournalActa Tropica
Volume238
Early online date8 Dec 2022
DOIs
Publication statusPublished - 1 Feb 2023

Keywords

  • Capacity development
  • Infrastructure upgrade
  • Networking
  • Sub-Saharan Africa
  • Sustainability
  • Training

Fingerprint

Dive into the research topics of 'Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: the PanACEA approach'. Together they form a unique fingerprint.

Cite this